By Fineline Cube Shanghai Henlius Biotech, Inc. (HKG: 2696) announced it has received marketing authorization from the European Commission (EC) for Poherdy, a biosimilar to Roche’s Perjeta (pertuzumab), marking a significant milestone in the company’s global oncology expansion strategy.
Regulatory Approval Summary
| Item | Detail |
|---|---|
| Approval Authority | European Commission (EC) |
| Product | Poherdy (pertuzumab biosimilar) |
| Reference Product | Roche’s Perjeta (pertuzumab) |
| Indications | HER2-positive breast cancer across neoadjuvant, adjuvant, and metastatic settings |
| Combination Therapy | Used with trastuzumab and chemotherapy |
| Market Access | Immediate commercial availability across all EU member states |
Clinical Indications & Therapeutic Applications
Neoadjuvant Treatment
- Adult patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer at high risk of recurrence
Adjuvant Treatment
- Adult patients with HER2-positive early-stage breast cancer at high risk of recurrence
Metastatic/Recurrent Treatment
- Adult patients with HER2-positive, metastatic or locally recurrent unresectable breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease
- Administered in combination with trastuzumab and docetaxel
Global Regulatory Timeline
| Date | Milestone | Jurisdiction |
|---|---|---|
| June 2022 | Exclusive global licensing agreement with Organon LLC | Global (ex-China) |
| December 2024 | NDA accepted for review | China (NMPA) |
| May 2025 | NDA accepted for review | Canada (Health Canada) |
| November 2025 | FDA approval granted | United States |
| April 2026 | EC approval granted | European Union |
Commercial Strategy & Partnership Framework
- Global Commercialization: Organon LLC holds exclusive license for worldwide commercialization excluding Chinese mainland, Hong Kong, Macau, and Taiwan
- Market Opportunity: Addresses €2.8 billion European HER2-positive breast cancer biologics market
- Competitive Positioning: First Chinese-developed pertuzumab biosimilar to achieve comprehensive global regulatory approvals
- Revenue Model: Royalty-based structure with Organon for international markets; direct commercialization in Greater China region
Strategic Implications
- Chinese Biotech Milestone: Represents one of the most successful global regulatory achievements by a China-based biopharmaceutical company
- Biosimilar Leadership: Establishes Henlius as a leader in complex oncology biosimilars with multi-jurisdictional approval capability
- Healthcare Economics: Expected to reduce treatment costs by 30–40% compared to originator product, improving patient access
- Pipeline Validation: Demonstrates Henlius’ capability to develop and gain approval for complex monoclonal antibody biosimilars
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, commercial partnerships, and market opportunities. Actual results may differ due to risks including market adoption rates, pricing pressures, and competitive dynamics in the biosimilar space.-Fineline Info & Tech